Product

Quadrivalent recombinant influenza Vaccine

Aliases

Flublok Quadravalent®, Quadrivalent recombinant influenza Vaccine (RIV4)

1 clinical trial

1 indication

Indication

Influenza Immunization

Clinical trial

A Phase I, Parallel, Randomized, Active-controlled, Multi-center, Dose-escalation Study With Early Safety Data Reviews to Assess Safety and Immunogenicity of One Monovalent Modified Influenza mRNA Vaccine Encapsulated in LNP, in Adults Aged 18 to 49 Years and 60 Years and Above.

Status: Completed, Estimated PCD: 2024-03-14